On TV, in magazines and on social media: glucagon-like peptide 1 (GLP-1) agonist drugs such as Mounjaro, Wegovy and, especially, Ozempic are inescapable right now.
In just a few short years, they have profoundly altered the way we view weight management and metabolic wellness, generating billions of dollars in the process.1
But this is only part of the story. The more mainstream GLP-1 agonists become, the more concerns grow surrounding their side-effects, as well as questions about accessibility and long-term efficacy.2,3
So what does this all mean for nutraceutical producers? We’ve already seen significant opportunities emerge for the development of “GLP-1 companion products” to soothe common symptoms and fill nutritional gaps, but could there be another way to tap into this undeniable demand?
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.